Miguel Sieler Head of Neovacs: "We develop a groundbreaking technology"

PARIS, June 19, 2014 (GLOBE NEWSWIRE) -- Neovacs, (Alternext Paris: ALNEV), is a leader in active immunotherapies for the treatment of autoimmune diseases. The company will participate to the first annual "French Life Sciences Days", a major event that will bring together French biotech and medtech companies listed on the NYSE Euronext exchange, on 25 & 26 June, with members of the French and North American financial community. In this TV interview, Miguel Sieler Neovacs CEO explained the strategy of the company for US investors.

To watch this TV interview, just click on this link or put this link directly in your browser

http://www.labourseetlavie.com/videos/entreprises-strategie-et-resultats/miguel-sieler-ceo-neovacs-explained-the-strategy,1707.html

Main discussion in this video :

What Neovacs is developing exactly ?

At what development stage are the Neovacs products ?

Company has 4 preclinical programs, which is the most advanced ?

Why are you coming to New York ?

About Neovacs : a French biotechnology company focused on the development of Kinoids, therapeutic vaccines for the treatment of autoimmune and inflammatory diseases like rheumatoid arthritis, Crohn's Disease and lupus. The goal of the Kinoid approach is enable patients to have a superior quality of life by providing access to safe treatments with sustained efficacy.

About Web Tv www.labourseetlavie.com : 100% News about Markets, Economics and Business Leaders. With more than 1.500 videos, this is the first database for listed companies in France.

Neovacs PR Pdf http://hugin.info/160718/R/1796173/618363.pdf

contact@neovacs.com
Miguel Sieler
+33 1 53 10 93 00

HUG#1796173

Source:Neovacs